0756 GMT - Roche delivered solid results in line with expectations but its diagnostics' profitability disappoints, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's core EBIT of its diagnostics unit missed Vontobel's estimates by 10.5% which surprises as only 1Q was still affected by the pandemic washout, the analyst says. Its 2025 guidance is conservative, unchanged under the new management, he adds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 30, 2025 02:56 ET (07:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。